食品伙伴网讯 2023年11月14日，据欧盟食品安全局（EFSA）消息，欧盟营养、新型食品和食物过敏源（NDA）研究小组就一种2 -岩藻糖基乳糖（2 -fucosyllactose）作为新型食品的安全性发表科学意见。
据了解，该2 -岩藻糖基乳糖是由大肠杆菌W (ATCC 9637)的衍生菌株(大肠杆菌SGR5)生产的。经过评估，专家小组得出结论，在提议的使用条件下，2 -岩藻糖基乳糖作为新型食品是安全的。部分原文报道如下：
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 2 -fucosyllactose (2 -FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 2 -FL, but it also contains d-lactose, l-fucose, fucosylgalactose, difucosyllactose, d-glucose and d-galactose, and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli SGR5) of E. coli W (ATCC 9637). The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant applies for the same 澳洲幸运5
use and use levels as already authorised for 2 -FL and included in the Unio list of NFs, with the general population as target population. The Panel noted that the available intake estimate is not recent (2015) and based on a different database (2008 2010 UK data) than that used by EFSA. For this reason, the Panel decided to perform a new intake estimate according to the current EFSA approach. The Panel notes that the highest P95 daily intake of the NF from the use as food ingredient is higher than the estimated natural highest mean daily intake in breastfed infants and marginally higher in young children. The applicant also proposes to extend the use of 2 -FL in food supplements (FS) for infants at the use level of 1.2?g/day. The resulting estimated intake in infants from the proposed use in FS is within the natural intake of 2 -FL in breastfed infants. FS are not intended to be used if other foods with added 2 -FL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.